TWI241167B - Improved pediatric formula and methods for providing nutrition and improving tolerance - Google Patents
Improved pediatric formula and methods for providing nutrition and improving tolerance Download PDFInfo
- Publication number
- TWI241167B TWI241167B TW090102265A TW90102265A TWI241167B TW I241167 B TWI241167 B TW I241167B TW 090102265 A TW090102265 A TW 090102265A TW 90102265 A TW90102265 A TW 90102265A TW I241167 B TWI241167 B TW I241167B
- Authority
- TW
- Taiwan
- Prior art keywords
- protein
- infant
- grams
- child
- blend
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 17
- 235000016709 nutrition Nutrition 0.000 title abstract description 17
- 230000035764 nutrition Effects 0.000 title abstract description 9
- 230000001976 improved effect Effects 0.000 title abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 70
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 70
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 52
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 51
- 239000000230 xanthan gum Substances 0.000 claims abstract description 51
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 51
- 239000000843 powder Substances 0.000 claims abstract description 36
- 150000002632 lipids Chemical class 0.000 claims abstract description 29
- 239000003381 stabilizer Substances 0.000 claims abstract description 19
- 229940088594 vitamin Drugs 0.000 claims abstract description 18
- 229930003231 vitamin Natural products 0.000 claims abstract description 18
- 235000013343 vitamin Nutrition 0.000 claims abstract description 18
- 239000011782 vitamin Substances 0.000 claims abstract description 18
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 15
- 239000011707 mineral Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims description 207
- 235000018102 proteins Nutrition 0.000 claims description 68
- 238000011049 filling Methods 0.000 claims description 30
- 235000000346 sugar Nutrition 0.000 claims description 25
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 22
- 239000003531 protein hydrolysate Substances 0.000 claims description 22
- 230000002079 cooperative effect Effects 0.000 claims description 16
- 235000013336 milk Nutrition 0.000 claims description 16
- 239000008267 milk Substances 0.000 claims description 16
- 210000004080 milk Anatomy 0.000 claims description 16
- 229940024606 amino acid Drugs 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 150000008163 sugars Chemical class 0.000 claims description 15
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 240000007594 Oryza sativa Species 0.000 claims description 12
- 235000007164 Oryza sativa Nutrition 0.000 claims description 12
- 235000019485 Safflower oil Nutrition 0.000 claims description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 12
- 235000009566 rice Nutrition 0.000 claims description 12
- 235000005713 safflower oil Nutrition 0.000 claims description 12
- 239000003813 safflower oil Substances 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 10
- 244000061456 Solanum tuberosum Species 0.000 claims description 9
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 240000008042 Zea mays Species 0.000 claims description 9
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 9
- 235000005822 corn Nutrition 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 8
- 239000003549 soybean oil Substances 0.000 claims description 8
- 235000012424 soybean oil Nutrition 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 7
- 229920000591 gum Polymers 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 235000019486 Sunflower oil Nutrition 0.000 claims description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 6
- 239000011575 calcium Substances 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 239000002600 sunflower oil Substances 0.000 claims description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 244000068988 Glycine max Species 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- 235000010489 acacia gum Nutrition 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 239000003240 coconut oil Substances 0.000 claims description 5
- 235000019864 coconut oil Nutrition 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- -1 glycerin Triester Chemical class 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 229960003080 taurine Drugs 0.000 claims description 5
- 229960004441 tyrosine Drugs 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 108010073771 Soybean Proteins Proteins 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 235000015278 beef Nutrition 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 4
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 229960004799 tryptophan Drugs 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 235000016804 zinc Nutrition 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 claims description 3
- 102000011632 Caseins Human genes 0.000 claims description 3
- 108010076119 Caseins Proteins 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 claims description 3
- 108010028690 Fish Proteins Proteins 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 229920002148 Gellan gum Polymers 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 235000019482 Palm oil Nutrition 0.000 claims description 3
- 108010084695 Pea Proteins Proteins 0.000 claims description 3
- 108010064851 Plant Proteins Proteins 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 235000021120 animal protein Nutrition 0.000 claims description 3
- 229940114079 arachidonic acid Drugs 0.000 claims description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims description 3
- 239000000305 astragalus gummifer gum Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 229960004203 carnitine Drugs 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 235000005687 corn oil Nutrition 0.000 claims description 3
- 239000002285 corn oil Substances 0.000 claims description 3
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 claims description 3
- 235000013350 formula milk Nutrition 0.000 claims description 3
- 235000010492 gellan gum Nutrition 0.000 claims description 3
- 239000000216 gellan gum Substances 0.000 claims description 3
- 235000019534 high fructose corn syrup Nutrition 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 239000003346 palm kernel oil Substances 0.000 claims description 3
- 235000019865 palm kernel oil Nutrition 0.000 claims description 3
- 239000002540 palm oil Substances 0.000 claims description 3
- 235000019702 pea protein Nutrition 0.000 claims description 3
- 235000021118 plant-derived protein Nutrition 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 235000011649 selenium Nutrition 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 240000004731 Acer pseudoplatanus Species 0.000 claims description 2
- 235000002754 Acer pseudoplatanus Nutrition 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 229930195722 L-methionine Natural products 0.000 claims description 2
- 229920000161 Locust bean gum Polymers 0.000 claims description 2
- 240000003183 Manihot esculenta Species 0.000 claims description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 2
- 102000014171 Milk Proteins Human genes 0.000 claims description 2
- 108010011756 Milk Proteins Proteins 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000006485 Platanus occidentalis Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims description 2
- 235000019519 canola oil Nutrition 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 235000010420 locust bean gum Nutrition 0.000 claims description 2
- 239000000711 locust bean gum Substances 0.000 claims description 2
- 229960004452 methionine Drugs 0.000 claims description 2
- 235000021239 milk protein Nutrition 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 2
- 229930064664 L-arginine Natural products 0.000 claims 2
- 235000014852 L-arginine Nutrition 0.000 claims 2
- 235000019710 soybean protein Nutrition 0.000 claims 2
- 244000215068 Acacia senegal Species 0.000 claims 1
- 244000208874 Althaea officinalis Species 0.000 claims 1
- 235000006576 Althaea officinalis Nutrition 0.000 claims 1
- 240000001592 Amaranthus caudatus Species 0.000 claims 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 claims 1
- 244000105624 Arachis hypogaea Species 0.000 claims 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims 1
- 240000008886 Ceratonia siliqua Species 0.000 claims 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims 1
- 240000007472 Leucaena leucocephala Species 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 239000004368 Modified starch Substances 0.000 claims 1
- 241000282376 Panthera tigris Species 0.000 claims 1
- 240000002834 Paulownia tomentosa Species 0.000 claims 1
- 235000019484 Rapeseed oil Nutrition 0.000 claims 1
- 235000012735 amaranth Nutrition 0.000 claims 1
- 239000004178 amaranth Substances 0.000 claims 1
- 235000017803 cinnamon Nutrition 0.000 claims 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims 1
- 229940099500 cystamine Drugs 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 235000001035 marshmallow Nutrition 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- 235000020232 peanut Nutrition 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 abstract description 10
- 239000012141 concentrate Substances 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000035611 feeding Effects 0.000 description 22
- 239000002002 slurry Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 19
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 9
- 206010047700 Vomiting Diseases 0.000 description 9
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 239000005913 Maltodextrin Substances 0.000 description 8
- 229920002774 Maltodextrin Polymers 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 210000003608 fece Anatomy 0.000 description 8
- 229940035034 maltodextrin Drugs 0.000 description 8
- 230000008673 vomiting Effects 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 230000013872 defecation Effects 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000002689 soil Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 6
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 6
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 6
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 description 6
- 235000010216 calcium carbonate Nutrition 0.000 description 6
- 239000001506 calcium phosphate Substances 0.000 description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 description 6
- 235000011010 calcium phosphates Nutrition 0.000 description 6
- 235000010418 carrageenan Nutrition 0.000 description 6
- 239000000679 carrageenan Substances 0.000 description 6
- 229920001525 carrageenan Polymers 0.000 description 6
- 229940113118 carrageenan Drugs 0.000 description 6
- 108010079058 casein hydrolysate Proteins 0.000 description 6
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 235000011147 magnesium chloride Nutrition 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 235000011164 potassium chloride Nutrition 0.000 description 6
- 239000001508 potassium citrate Substances 0.000 description 6
- 229960002635 potassium citrate Drugs 0.000 description 6
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 6
- 235000011082 potassium citrates Nutrition 0.000 description 6
- 235000007715 potassium iodide Nutrition 0.000 description 6
- 235000019172 retinyl palmitate Nutrition 0.000 description 6
- 239000011769 retinyl palmitate Substances 0.000 description 6
- 229940108325 retinyl palmitate Drugs 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 229930003799 tocopherol Natural products 0.000 description 6
- 229960001295 tocopherol Drugs 0.000 description 6
- 235000010384 tocopherol Nutrition 0.000 description 6
- 239000011732 tocopherol Substances 0.000 description 6
- 229940042585 tocopherol acetate Drugs 0.000 description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
- 235000005282 vitamin D3 Nutrition 0.000 description 6
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 6
- 239000011647 vitamin D3 Substances 0.000 description 6
- 229940021056 vitamin d3 Drugs 0.000 description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 6
- 229930003448 Vitamin K Natural products 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 235000019168 vitamin K Nutrition 0.000 description 5
- 239000011712 vitamin K Substances 0.000 description 5
- 150000003721 vitamin K derivatives Chemical class 0.000 description 5
- 229940046010 vitamin k Drugs 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 235000019742 Vitamins premix Nutrition 0.000 description 4
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 206010011469 Crying Diseases 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- YSAVZVORKRDODB-UHFFFAOYSA-N Diethyl tartrate Chemical compound CCOC(=O)C(O)C(O)C(=O)OCC YSAVZVORKRDODB-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 239000000413 hydrolysate Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 235000006180 nutrition needs Nutrition 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- DYTUAOUIQFNOIH-UHFFFAOYSA-N 2,3-diethyl-2,3-dihydroxybutanedioic acid Chemical compound CCC(O)(C(O)=O)C(O)(CC)C(O)=O DYTUAOUIQFNOIH-UHFFFAOYSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- 229960000355 copper sulfate Drugs 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 229960002104 cyanocobalamin Drugs 0.000 description 2
- 235000000639 cyanocobalamin Nutrition 0.000 description 2
- 239000011666 cyanocobalamin Substances 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229960004839 potassium iodide Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 2
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 2
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- DAULJXMTHKRKSK-JIZZDEOASA-N (2r)-2-amino-3-sulfanylpropanoic acid;sodium Chemical compound [Na].[Na].SC[C@H](N)C(O)=O DAULJXMTHKRKSK-JIZZDEOASA-N 0.000 description 1
- AFSHUZFNMVJNKX-UHFFFAOYSA-N 1,2-di-(9Z-octadecenoyl)glycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCC=CCCCCCCCC AFSHUZFNMVJNKX-UHFFFAOYSA-N 0.000 description 1
- AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010017367 Frequent bowel movements Diseases 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- HHGZUQPEIHGQST-UHFFFAOYSA-N [2-[(2-azaniumyl-2-carboxyethyl)disulfanyl]-1-carboxyethyl]azanium;dichloride Chemical compound Cl.Cl.OC(=O)C(N)CSSCC(N)C(O)=O HHGZUQPEIHGQST-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000012075 bio-oil Substances 0.000 description 1
- UBSLUAKFONPTMY-UHFFFAOYSA-N bis(2,3-dihydroxypropyl) 2,3-dihydroxybutanedioate Chemical compound OCC(O)COC(=O)C(O)C(O)C(=O)OCC(O)CO UBSLUAKFONPTMY-UHFFFAOYSA-N 0.000 description 1
- BFHRUCFCIXWADD-UHFFFAOYSA-N bis(ethenyl) 2,3-dihydroxybutanedioate Chemical compound C=COC(=O)C(O)C(O)C(=O)OC=C BFHRUCFCIXWADD-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229940106705 chlorophyll Drugs 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- KRGPXXHMOXVMMM-UHFFFAOYSA-N nicotianamine Natural products OC(=O)C(N)CCNC(C(O)=O)CCN1CCC1C(O)=O KRGPXXHMOXVMMM-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
- A23L29/27—Xanthan not combined with other microbial gums
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S426/00—Food or edible material: processes, compositions, and products
- Y10S426/801—Pediatric
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Pediatric Medicine (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Description
1241167 ΑΊ 五、發明説明(1 ) 發明領域: (請先閱讀背面之注意事項再填寫本頁) 本發明係關於一種嬰幼兒調和物,且特別是關於能強 化餵食該調和物之嬰幼兒患者之耐受性之調和物。嬰幼兒 患者包括.嬰兒(1 2個月大或較小之小孩)及孩童(超過1 2個月 大但小於13歲之小孩)兩者。(所以,所有的嬰兒都是小孩, 但非所有的小孩都是嬰兒)。更特殊地,本發明係關於一種 含有黃原膠之嬰幼兒調和物,黃原膠已被發現到能有效增 強餵食此種調和物之患者的耐受性。本發明亦爲一種提供 營養的方法及一種改善耐受性的方法,其包含投予有效份 量之一種含有黃原膠之嬰幼兒調和物。 發明背景: 嬰幼兒調和物基於蛋白質的類型可分成三種常見類型: 以完整蛋白質爲主,以水解過的蛋白質爲主,及以游離胺 基酸爲主(嬰幼兒調和物包括嬰兒調和物及適用於一歲大及 更年長的兒童之調和物)。除了蛋白質來源以外,市售的嬰 幼兒調和物還可含有醣類、脂質、維生素及礦物質。近來 使用游離胺基酸作爲一歲大或以上之嬰幼兒調和物( 經濟部智慧財產局員工消費合作社印製
EleCare™,Ross Products Division of Abbott Laboratories )中之嬰幼兒營養來源,其具有如下一或多種問題:消化及吸 收一般食物的問題,造成食物過敏,消化道問題,或其它 需要基礎飮食的情況。 許多:嬰幼兒患者經歷過對特定調和物有不耐受性的情 形(調和物不耐受性)。術語不耐受性及調和物不耐受性在此 本纸張尺度適用中國國家摞準(CNS ) A4規格(210X 297公釐) -4 - 1241167 A7 B7 五、發明説明(2) (請先閱讀背面之注意事項再填寫本頁) 被交替使用著。不耐受性爲一種非免疫系統的反應且可藉 著行爲或糞便或饌食類型的變化來證實,例如.與一般可以 良好耐受該等調和物之嬰兒相比較時,具有不耐受性之嬰 兒有溢奶或吐奶增加,糞便次數增多,糞便較爲水樣,及 較爲吵鬧的現象。不耐受性更常藉由消化道症狀(例如嘔吐 、糞便型武及放屁)以及行爲特徵(例如對調和物的接受性、 吵鬧及哭泣)來顯示。於臨床硏究中,呈現此等行爲常是導 致父母親將他們的嬰兒退出一項特殊硏究的原因。由於此 等行爲而造成嬰兒退出硏究時則稱爲不耐受性退出(硏究)。 於非臨床情況下呈現此等行爲會使得父母親更換所用調和 物。 經濟部智慧財產局員工消費合作社印製 可將不耐受性與某些嬰兒對於特定調和物所顯現的過 敏性反應作比較。此等過敏性反應結合有免疫系統的反應 ,且可能係由於嬰兒對於存在於該調和物中的蛋白質之敏 感性所造成的。許多對於完整蛋白質例如以完整的牛乳蛋 白質爲主或以完整大豆蛋白質分離物爲主的調和物顯示出 過敏性或敏感性的嬰兒,則可以耐受充份水解的蛋白質。( 水解物調和物(亦被稱爲半-基礎調和物)含有已被水解過或 分解成短肽片段及胺基酸之蛋白質,故而可以更容易地爲 全部的嬰兒所消化)。此等與免疫系統有關的過敏性或敏感 性通常會造成表皮的、呼吸系統的或消化系統的症狀例如 嘔吐及下痢。對完整蛋白質調和物有反應的嬰兒通常對於 水解物類調和物不會有反應’因爲他們的免疫系統不會將 水解過的蛋白質視爲該等會造成過敏症狀的完整蛋白質。 ϋ張尺^適用ί國國家標準(cNS)A4規格(210 x 297公董) Γ ^ 1241167 A7 B7 五、發明説明(3) (請先閲讀背面之注意事項再填寫本頁) 對於調和物表現出與免疫系統有關之反應的嬰兒也可能會 顯現出如前文所述般與非免疫系統有關的反應(調和物不耐 受性)。 現在存在有許多不同的嬰幼兒調和物。在此技術中目 前的重點多在於調和物的物理安定性,以及同時加工或製 造的考量。
Mas son之美國專利第5, 1 9 2,5 7 7號揭露且教示使用黃原 膠於營養調和物中,但在該調和物中黃原膠僅被用來作爲 安定劑且特殊地限制其在該調和物中的使用,於該調和物 中係使用卡帕鹿角聚糖(k a ρ p a c a r 1· a g e e n a η)與該黃原膠組合 。Massed主要係在解決其所揭示之營養調和物的物理安定 性且並沒有陳述餵食該種調和物之患者所顯現的不耐受性 的問題。:
Smidt等人之美國專利第5,472,952號則有關營養完整的 食品組成物,其含有部份水解的果膠以控制下痢的情形。 其揭示使#用黃原膠作爲乳化劑或安定劑但並沒有教示所提 供之黃原膠的份量。 經濟部智慧財產局員工消費合作社印製
Antnione等人的美國專利第5,681,600號揭示營養調和物 中黃原膠之使用,但卻教示黃原膠的使用係難以接受的, 因爲在使用含有黃原膠的調和物時會有不良的鈣運輸現象 〇
Mahmoud之美國專利第4,670,268號揭示一種含有黃原膠 之腸道低過敏性之營養調和物’但是其並沒有提供任何達 成該目的所需黃原膠之有效份量之教示。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) -6 - 1241167 • A7 ___ B7_ 五、發明説明(4) (請先閲讀背面之注意事項再填寫本頁)
Montezi n os之美國專利第5,9 19,5 12號揭示在有味道/混 濁狀乳液如稀釋果汁及茶類飮品中使用黃原膠作爲安定劑 。其中所揭示的乳液不含有蛋白質,所以並不適於作爲嬰 幼兒調和物。
DeWUle等人之美國專利第5,5 97,5 9 5號揭示在強化鈣及 維生素D含量之低pH値飮料中使用黃原膠作爲乳化安定劑。 於DeWille等人之美國專利第5,817,351號揭示在強化鈣 含量之低pH値飲料中使用黃原膠作爲安定劑。其所揭示之 飲料不含有脂肪及蛋白質且將不適於作爲完整的營養來源 〇
Chandler等人之美國專利第5,609,897號揭示在類似不含 酒精飲料之粉末調製飲品中使用黃原膠,該飲品已強化鈣 及維生素D含量。 C h a n d 1 e_r等人之美國專利第5,8 5 8,4 4 9號揭示在異黃酮-富化大豆爲主之冷凍點心中黃原膠之使用。 經濟部智慧財產局員工消費合作社印製 一般..而言,在先前技術的營養調和物中完全沒有述及 不耐受性的問題。所以,對於顯現不耐受性症狀的嬰幼兒 患者提供.一種可更輕易地耐受的調和物爲一種尙未被滿足 的需求。一種可以更良好地耐受的調和物可使得顯現不耐 受症狀的嬰幼兒在行爲上表現得更類似於能良好耐受調和 物之一般嬰幼兒所顯現的行爲。 發明目的·及槪述: 本發明提供一種改良的嬰幼兒調和物以及提供餵食該 本纸張尺度適用中國國家標準(CNS ) A4規格(210父297公^^ 1241167 A7 B7 五、發明説明(5 ) (請先閱讀背面之注意事項再填寫本頁) 調和物之兒童營養並增加餵食該調和物之兒童的耐受丨生白勺 方法。(在此使用時,除非另有說明’術語兒童包括嬰兒及 一歲以上之幼童兩者。術語兒童(單數/多數)及嬰幼兒患、者 亦交替使用)。黃原膠的使用無法預期地提供對耐受性的改 善作用。該調和物亦可爲濃縮液,即食形式或粉末形式。 該調和物於每100仟卡中含有約8到約1 6克醣類(較佳地約9.4 克到約12.3克),約3克到約6克脂質(較佳地約4.7克到約5.6 克),約1 · 8克到約3 · 3克蛋白質(較佳地約2 · 4克到約3.3克), 及含有約37毫克到約370毫克黃原膠(較佳地約74到約222毫 克,更佳.地約1 1 1到約1 4 8毫克)之耐受性改良劑。若該調和 物係以粉末狀形式來提供,於每100克粉末中其含有約30到 約90克醣類(較佳地約48到約59克),約15到約3〇克脂質(較 佳地約20到約30克),約8到約17克蛋白質(較佳地約1〇到約 1 7克),及約1 8 8到約1 8 8 0毫克黃原膠(較佳地約3 7 5到約1 1 2 5 毫克,更佳地約565到約750毫克)。 經濟部智慧財產局員工消費合作社印製 該調和物可進一步含有一種安定劑且亦可較佳地含有 維生素及礦物質,其份量足以供應嬰兒或一歲以上幼童的 每曰營養.需求。當該調和物爲一種嬰兒調和物時,諸維生 素及礦物質的份量較佳地係根據FD A指南來決定。當嬰兒係 用本發明.之調和物來餵食時,當與餵食同一組成但缺乏該 耐受性改良劑的調和物之嬰兒作比較時,該等餵食本發明 調和物之嬰兒會顯示出較佳的耐受性。 本發明亦提供供應嬰幼兒患者營養及改善耐受性的方 法。該等方法包含餵食孩童有效份量之如下調和物,該調 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -8 - 1241167 A7 五、發明説明(6) (請先閲讀背面之注意事項再填寫本頁) 和物於每100仟卡中含有約8到約1 6克醣類(較佳地約9.4克到 約1 2 · 3克),約3克到約6克脂質(較佳地約4.7克到約5 · 6克), 約1 · 8克到約3 · 3克蛋白質(較佳地約2 · 4克到約3.3克),及含有 約3 7毫克到約3 7 0毫克黃原膠(較佳地約7 4到約2 2 2毫克,更 佳地約1 Π到約1 4 8毫克)之耐受性改良劑。若該調和物係以 粉末狀形式來提供,於每1 0 0克粉末中其含有約3 0到約9 0克 醣類(較佳地約48到約59克),約15到約30克脂質(較佳地約 2 2到約2 8克),約8到約1 7克蛋白質(較佳地約1 1到約1 7克), 及約1 8 8到約.1 8 8 0毫克黃原膠(較佳地約3 7 5到約1 1 2 5毫克, 更佳地約5 65到約750毫克)。餵食本發明調和物之孩童較餵 食同一組成但缺乏該黃原膠耐受性改良劑之調和物之孩童 顯示出較少不耐受性的症狀。 發明詳紙說明: 經濟部智慧財產局員工消費合作社印製 本發明提供一種改良的嬰幼兒調和物,其可減輕餵食 該調和物之孩童的不耐受性。本發明亦提供供應不耐受性 患者營養且改善其耐受性的方法,其包含餵食孩童本發明 之調和物。黃原膠的使用對於耐受性提供了無法預知的改 善作用。 嬰兒耐受性(調和物耐受性)通常係藉著消化道症狀(如 嘔吐、糞便形式及放屁排氣)以及行爲特徵(如對調和物的接 受性,吵鬧及哭泣)來顯示。基於本發明的目的,耐受性的 改善(或不耐受性的減輕)係以如下一或多種症狀或特性的改 善(趨向正常形式的改變)來定義:糞便形式、吐奶、溢奶' 本紙張尺度適用中國國家標準(CNS ) A4規格(210x 297公釐) -9- 1241167 Α7 Β7 五、發明説明(7) 對調和物的接受性、吵鬧、哭泣,或不耐受性退出(硏究)( 臨床性的標準)。 (請先閱讀背面之注意事項再填寫本頁) 本發明之嬰幼兒調和物可以粉末、濃縮液或即食( ready-to-feed)形式來提供。於餵食前,將水加到粉末及濃 縮物开> 式的g周和物中。於第一具體例中,本發明之嬰幼兒 調和物於每100仟卡中含有約8到約16克醣類(較佳地約9.4克 到約12.3克),約3克到約6克脂質(較佳地約4。7克到約5· 6克) ,約1.8克到約3.3克蛋白質(較佳地約2.4克到約3.3克),及含 有約37毫克到約370毫克黃原膠(較佳地約74到約222毫克, 更佳地約1 1 1到約1 4 8毫克)之耐受性改良劑。若該調和物係 以粉末狀’形式來提供,於每1 〇 〇克粉末中其含有約3 〇到約9 〇 克醣類(較佳地約48到約59克),約15到約30克脂質(較佳地 約2 2到約2 8克),約8到約1 7克蛋白質(較佳地約1 1到約1 7克) ,及約1.88到約1 8 80毫克黃原膠(較佳地約37 5到約1 125毫克 ,更佳地約5 6 5到約7 5 0毫克)。本發明調和物中(每1〇〇仟卡 ,每100克粉末及每1公升中)醣類、脂質及蛋白質量的範圍 總述係示於表I。 經濟部智慧財產局員工消費合作社印製 黃原膠爲一種藉著黃桿菌力酉發 酵醣類所產生的高分子量多醣類。雖然有多種不同粒度的 黃原膠可供使用,但是於本發明中黃原膠的使用並不限於 特殊粒度之黃原膠。適當的粒度可基於加工參數來選擇, 例如如果黃原膠係乾燥混入調和物時則以較細粒度(200篩目 )者爲佳,然而如果黃原膠不是乾燥混入調和物中時則以較 粗粒度者(80篩目)爲宜。一種可用於本發明之適當黃原膠爲 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X 297公釐) -10- 1241167 Α7 Β7 五、發明説明(8) 購自K e 1 c 〇,a d 1 v i s 1 ο η 〇 f Μ ο n s a n t 〇,芝加哥,依利諾州之 Keltr〇l-F黃原膠(200篩目)。 (請先閲讀背面之注意事項再填寫本頁) 適當的醣類、脂質及蛋白質可有廣泛的變化且爲熟悉 製造嬰幼兒調和物之技術者所習知。所以適當的醣類可包 括但不限於水解過的、完整的、天然的及/或化學修改過的 Μ粉來源,其可來自玉米、樹薯、米或馬鈴薯糯質或非糯 質的形式;以及糖類如葡萄糖、果糖、乳糖、蔗糖、麥芽 糖,高果糖量玉米糖漿、及其混合物。麥芽糖糊精爲多醣 ’其爲從源粉如玉米或米之源粉用酸或酶水解而製得。其 分類係基於水解程度且被稱爲葡萄糖當量(dextrose equ1Valent(DE))。當以蛋白質水解物作爲水解來源時,任何 所使用之麥芽糖糊精的DE値最好是小於約18-20。當以蛋白 質水解物作爲蛋白質來源時,最好以避免會導致過量梅納 S應之褐變產物生成的情形。 經濟部智慧財產局員工消費合作社印製 適當的脂質包括但不限於椰子油、豆油、玉米油、橄 欖油、..紅花油、高油酸紅花油、M C T油A (中等鏈長甘油三 酯)、葵布油、高油酸量葵花油、棕櫚油、棕櫚仁油、低芥 酸含量之油菜油(canola 〇Π)、花生四烯酸及二十二碳六烯 酸之脂質來源,及其混合物。花生四烯酸及二十二碳六烯 酸之脂質來源包括但不限於海洋生物油、卵黃油及真菌油 〇 · 適當的蛋白質來源包括乳汁、大豆、米、肉(如牛肉)、 動物及植物(如豌豆、馬鈴薯)、蛋(卵白)、明膠及魚。適當 的完整軍.白質包括但不限於大豆爲主之蛋白質、乳汁爲主 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X 297公慶) -11 - 1241167 A7 B7 i、發明説明(9) (請先閲讀背面之注意事項再填寫本頁} 經濟部智慧財產局員工消費合作社印製 之蛋白質、酪蛋白蛋白質、乳淸蛋白質、米蛋白質、牛肉 膠原蛋白、.豌豆蛋白質、馬鈴薯蛋白質及其混合物。適當 的蛋白質水解物亦包括但不限於大豆蛋白質水解物、酪蛋 白蛋白質水解物、乳淸蛋白質水解物、米蛋白質水解物、 馬鈴薯蛋白質水解物、魚蛋白質水解物、卵白蛋白質水解 物、明膠蛋白質水解物、動物及植物蛋白質水解物的組合 ’及其混合物。水解過的蛋白質(蛋白質水解物)爲已被水解 或分解成較短肽片段及胺基酸之蛋白質。此等水解過的肽 片段及游離胺基酸更容易被消化。就廣義而言,當一或多 處醯胺鍵已被破壞掉時則蛋白質已被水解。醯胺鍵的破壞 可在製造時例如由於加熱或剪切作用而非蓄意地或意外地 產生。就本發明的目的而言,術語水解過的蛋白質意指以 蓄意破壞醯胺鍵的方式來加工過或處理過的蛋白質。蓄意 水解可以例如藉著用酶或酸來處理完整蛋白質來作用。用 於本發明調和物之較佳的水解過蛋白質係被水解成其中胺 基氮素(AN)對總氮素(TN)之比例的範圍在約0.1 AN對1.0TN 到約0·4AN對約1·0TN,較佳地約0·25AN對1·0TN至約0.4AN 對約1.0TN。(在此所提出的AN:TN比例只爲該水解物蛋白質 源的比例,而非代表在最終嬰幼兒營養調和物產物中的AN: TN比例,因爲可將游離胺基酸作爲補充物來加入而改變前 述數値。)蛋白質亦可以游離胺基酸的形式來提供。本發明 之調和物較佳地補充有多種不同的游離胺基酸以提供營養 更完整均的調和物。適當游離胺基酸的實例包括但不限 於色胺酸、酪胺酸、胱胺酸、牛磺酸、L·精胺酸、L-甲硫胺 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -12- 1241167 A7 B7 五、發明説明( 酸及肉毒鹼。 (請先閲讀背面之注意事項再填寫本頁) 較佳地本發明之調和物亦含有礦物質及維生素,其份 量係設定成可供應一嬰幼兒患者之每日營養需求量。該調 和物較佳地包含但不限於如下維生素及礦物質:錦、磷、鈉 、氯、鎂、猛、鐵 '銅、鋅、硒 '碘及維生素A、Ε、C、D ' K及B群。對於嬰兒調和物進一步的營養指南可見於嬰兒 調和物法案,U.S.C.第21章,第350(a)條。在該嬰兒調和物 法案中所見到的營養指南隨著有關嬰幼兒營養需求之進一 步硏究的完成會持續地再修正。本發明意圖涵蓋之調和物 其可包括目前並未被列在該法案中的礦物質及維生素。 .於本發明之第二具體例中,本發明之調和物進一步含 有一安定劑。用於嬰幼兒營養調和物之適當安定劑爲熟悉 此技術者所習知。適當的安定劑包括但不限於阿拉伯膠、 印度膠、.梧桐膠、黃蓍膠、洋菜、叉纖維聚糖(furcellaran) 、瓜爾膠(guar gum)、傑倫膠(gellan gum)、角豆膠、果膠 、低甲氧、膠、明膠 '微晶纖維素、CMC(羧甲基纖維素鈉) '甲基纖維素、羥丙基甲基纖維素、羥丙基纖維素、 經濟部智慧財產局員工消費合作社印製 DATEM(甘油單酯及甘油二酯之二乙醯基酒石酸酯)、葡聚糖 、角叉菜膠、及其混合物。本發明調和物較佳地不含有^ 角叉菜膠作爲安定劑,最好不含有角叉菜膠。如果所使用 的任何角叉菜膠主要係呈其它形式(6或λ )則該調和物係被 定義爲不含有/c角叉菜膠。所用安定劑的份量將視所選用 的安定劑、其它倂存的成份,及所尋求之調和物之安定性 及黏度而有所不同。基於於該調和物中所追求的特性(如黏 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ 297公釐) -13 - 1241167 Α7 Β7 五、發明説明(11) 度),其適當的份量爲熟悉此技術之人士可輕易決定的。 、 (請先閲讀背面之注意事項再填寫本頁) 本發明亦提供供應一嬰幼兒患者營養且改善其耐受性 的方法。該等方法包括餵食孩童一有效份量之如下調和物 ’該調和物於每100仟卡中含有約8到約16克醣類(較佳地約 9 ·4克到約12.3克),約3克到約6克脂質(較佳地約4.7克到約 5· 6克),約1.8克到約3.3克蛋白質(較佳地約2.4克到約3.3克) 5及含有約37毫克到約37 0毫克黃原膠(較佳地約74到約222 毫克,更佳地約1 1 1到約1 4 8毫克)之耐受性改良劑。若該調 和物係以粉末狀形式來提供,於每100克粉末中其含有約30 到約90克醣類(較佳地約48到約59克),約15到約30克脂質( 較佳地約22到約28克),約8到約17克蛋白質(較佳地約1 1到 約17克),及約188到約1 880毫克黃原膠(較佳地約375到約 1125毫克,更佳地約565到約750毫克)。 經濟部智慧財產局肖工消費合作社印製 於其它具體例中,該調和物進一步含有一安定劑。其 它具體例亦較佳地含有維生素及礦物質,其份量如前所述 。適當的醣類。脂質、蛋白質、及安定劑爲熟悉此技術者 所習知,且可包括但不限於前文所述之物質。較佳地,若 該調和物爲一種嬰兒調和物,該方法包含餵食嬰兒足夠份 量的該種調和物以滿足嬰兒每日所有的營養需求。 本發明之嬰幼兒調和物可使用熟悉此技術者習知的技 術來製造。存在有多種不同加工技術以製造粉狀、即食及 濃縮液型調.和物。典型地,此等技術包括從一或多種溶液 來形成漿液_,該等溶液可含有水及一或多種如下成份:醣類 、蛋白質、脂質、安定劑、維生素及礦物質。將此漿液乳 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) -14- 1241167 經濟部智慧財產局員工消費合作社印製 Α7 Β7 五、發明説明( 化、均質化及冷卻。在加工前、加工後或兩者時間下可以 將其它不同溶液加到該漿液中。然後將加工過的調和物消 毒且稀釋成可用即食形式來使用或以濃縮液或粉末來儲存 。若所產製的調和物打算作爲即食液或濃縮液的話,在消 毒前要加入適量水。若所產製的調和物打算作爲粉末,將 該漿液加熱且乾燥以獲得粉末。若需要,乾燥製得的粉末 可與進一步成份乾燥混合在一起。 如下實施例係用來顯示本發明改良嬰幼兒患者耐受性 之方法及組成物。雖然在下文中本發明實施例係以粉末狀 的嬰兒營養調和物來作說明,但其並不意味著要如此來限 定本發明,因爲本發明意圖涵蓋即食型及濃縮液型的嬰兒 調和物以及適用於一歲或一歲以上之孩童之調.和物。此等 實施例並不具有限制性,因爲在不悖離本發明之精神下還 可使用其它醣類、脂質、蛋白質、安定劑、維生素及礦物 質。 實施例1-臨床硏究 下文爲以四種不同的調和物中之其中一種調和物來餵 食之嬰兒其耐受性之臨床硏究的結果槪述。其係採用三種 不同之本發明調和物及一種對照組調和物(除了缺少黃原膠 耐受性改良劑以外,其它成份則完全相同)。係對健康的、 足月且年齡小於或等於2 8天之嬰兒來進行掩蓋地、隨機地 平行耐受性硏究。嬰兒先用即食型市售AHmentum-Proteui H y d r ο 1 y s a t e F 〇 r m u ] a w i t h I r ο η (含鐵蛋白質水解物調和物)( 本纸張尺度適用中國國家標準(CNS ) Α4規格(2】ΟΧ 297公釐) I---------%------、玎------» (請先閲讀背面之注意事項再填寫本頁) -15- 1241167 A7 B7 五、發明説明( (請先閱讀背面之注意事項再填寫本頁)
Ross Products Division,Abbott Laboratories)餵食一週以 作爲基線。接著嬰兒們立刻隨機地接受對照組調和物或調 和物B、C或D中的一種來餵食。除了在調和物B到D中存在 有不同份量的對照組調和物以外,該對照組調和物的組成 係與調和物B到D的組成完全相同。所有四種調和物的組成 係示於表II及IIA。該對照組調和物及調和物B到D係以置於 金屬罐中之粉末形式來提供,該金屬罐的大小足以在用水 沖泡重製時提供350克的份量。 經濟部智慧財產局員工消費合作社印製 若嬰兒符合下述條件才有資格參與硏究:健康良好; 妊娠週數滿37到42週的足月嬰兒;出生體重大於2500克;年 齡至少2 8天以上;在硏究期間都只使用調和物來饌食;雙 親已自願性地簽妥同意書;雙親同意不給予嬰兒礦物質或 維生素補充品;雙親同意在硏究期間只餵食他們的嬰兒該 硏究用調和物;該嬰兒爲單胎懷孕;母親不具有會不良地 影響胎兒的醫療病史,例如糖尿病、肺結核、生產時感染 、或嗤藥;嬰兒並沒有顯示出有心臟、呼吸系統、消化系統 、血液學的或代謝疾病的證據;當母親患有妊娠糖尿病時 嬰兒出生體重不超過95百分位(NCHS(國家健康統計中心))。 由硏究者來對當地族群中的嬰兒進行鑑定,且選出合 格的嬰兒。從三個不同的地方全部有1 82名嬰兒被選入此硏 究中。在最初的182名嬰兒中,有45名在基線期退出硏究, 且從沒有接受過對照組調和物或調和物B到D。在1 3 7名接受 對照組調和物或調和物B到D中的一種調和物之嬰兒中,有 12名兒無法完成硏究。 本^尺度適用中國) M規格U10X 297公釐) -16 - 1241167 A7 _一· _B7__ 五、發明説明(14 (請先閱讀背面之注意事項再填寫本頁y 硏究第1天係定義成進入此硏究的那一天。在第1天’ 係收集人口學資料/入場數據且使嬰兒脫去衣物稱重。雙親 們會收到約12罐32-fl oz的即食組成之Alimenturn含鐵蛋白 質水解物調和物作爲基線調和物。雙親們被教導在硏究第1 天的下午6點以前繼續以他們目前使用的調和物來餵食嬰兒 ,且於硏究第1天下午6點以後的第一餐開始用基線調和物 來饌食嬰兒。收集硏究第1天下午6點開始到第7天下午5點 5 9分爲止期間攝食量及糞便資料。雙親們也要記錄嬰兒糞 便的特售、每次餵食之調和物食用體積及溢奶與吐奶的情 形。 · 經濟部智慧財產局員工消費合作社印製 於硏究的第8天,硏究人員會檢視雙親們所完成記錄之 完整性及精確性,將嬰兒再度稱重且由雙親們對調和物的 滿意度及‘餵食與糞便型式等問題塡妥問卷。雙親們退回未 使用的基線調和物,而另被提供約4罐調和物,其爲對照組 調和物、調和物B、C或D中之一種指定的調和物。令雙親們 繼續餵食基線調和直至硏究第8天下午6點以前,然後則使 用該指定的調和物來餵食嬰兒且記錄餵食及糞便資訊。收 集硏究第8天下午6點開始到第1 4天下午5點5 9分爲止期間攝 食量及糞便資料。爲時六天收集有關該對照組調和物及調 和物B到D的資料。如同用基線調和物餵食般,在第1 5天訪 視時硏究人員會檢視雙親們在硏究第8天到第1 4天期間所完 成的每日攝取量及糞便記錄。於第1 5天,對嬰兒稱重,塡 妥問卷且雙親們退回任何該調和物未使用的部份。 本紙張尺度適用中國國家樣準(CM ) A4規格(210X29?公釐) -17 - 1241167 A7 B7 五、發明説明(β 統計分析 (請先閲讀背面之注意事項再填寫本頁) 主要的變數有每日排便次數平均値、糞便稠度平均等 級及吐奶與溢奶發生率。初步分析包括以意圖治療的基礎( i n t e n t -1 〇 -11· e a t b a s i s)來分析初步結果的變數。次級分析則 由完成硏究者來進行。硏究期間的數據係用位置(site)作爲 區段因子(blocking factor)以一元變異數分析來進行分析。 此外,還將硏究期間的數據作爲反應値且以基線數據作爲 共變値進行共離散分析以作爲確認性分析。適當時可進行 換算(該平方根之測距反正弦(r a n k i n g a 1· c s i n e))。使用偶發 性表法(c ο n t i n g e n c y t a b 1 e m e t h o d s)來分析分類/次序性數據 。所有測試都有兩面(t w ο - s i d e d)且以顯著値0 · 0 5來進行。在 三組初步分析中的顯著性使用Holm’s stepdown Bonferroni 方法來加'以調整以了解測試重複度(multiplicity of testing) 結果 .. 經濟部智慧財產局員工消費合作社印製 在硏究第1天時於各群組間都沒有發現到在人種特性及 年齡上有統計性的顯著差異。但在硏究剛開始時發現到群 組間的性別.分佈有顯著差異(P<0.05)。在硏究第1天時相較 於餵食對照組調和物的嬰兒組,餵食調和物B的嬰兒組體重 顯著性地較重。饌食對照組調和物的嬰兒由於不耐受性而 退出硏究的嬰兒數顯著性地多於餵食調和物B、c或D (其含 有黃原膠耐受性改良劑)之嬰兒。 在各群組間發現到每日排便平均次數有統計性地顯著 本紙張尺度適用中國國家標準(CNS ) A4規格(2]OX 297公釐) _ 1241167 Μ Β7 五、發明説明(10 差異(因重複度作調整後P = 〇.003)。相較於以調和物B(P二 0.000 1 )及D(P = 0.0073)來餵食的嬰兒,以該對照組調和物饌 食的嬰兒明顯地排便較多。在實驗期間(第8到1 4天)餵食對 照組調和物之嬰兒每日排便平均値爲2.7± 0.2次而用調和物 B及D饌食的嬰兒每日排便平均値則爲1.6土 0.2及2.1 ± 0.3次 。各群組間於糞便稠度平均等級上(mean rank stool c ο n s i s t e n c y)並沒有統計上地顯_差異。在各群組間水樣糞 便的比率則有顯著差異。當在分析中加入基線組測量値作 爲共變數時,餵食對照組調和物的嬰兒相較於餵食調和物B 及D的嬰兒顯著性地水樣糞便較多(P<0.01)。在各群組間並 沒有觀察到其它糞便參數(鬆散/泥狀便,軟便,成形糞便) 有顯著性地差異。每日排便次數、糞便稠度平均等級,水 樣便,鬆散/泥狀便,軟便及成形糞便的結果係示於表III。 於各群組間餵食時有溢奶的比例及餵食時有吐奶的比 例並沒有統計性地顯著差異。各群組間每日餵食次數,每 曰攝取量毫升數,或每日每公斤體重之攝取量毫升數並沒 有發現到有統計性地顯著差異。溢奶,吐奶,每日餵食次 數,每日攝取量毫升數及每日每公斤體重攝取量毫升數係 示於表IV。 在第1 5天時並沒有發現到在各群組間的重量NC H S Z-分數,或者實驗期間(第8-14天)的體重增加量有顯著差異。 但在第1 5天訪視時發現到各群組間嬰兒的體重有顯著差異 。餵食調和物Β的嬰兒比起在硏究第1天時更顯著性地比餵 食對照組調和物的嬰兒更重。當以硏究第8天的體重作爲共 本纸張尺度適用中國國家標準(CNS ) Α4規格(210X 297公釐) ----------- (請先閱讀背面之注意事項再填寫本頁) 、訂 經濟部智慧財產局員工消費合作社印製 -19 - 1241167 A7 B7 五、發明説明( 變數時,各群組間在硏究結束時的體重並沒有顯著差異。 結果係τρ;於表V。 (請先閲讀背面之注意事項再填寫本頁) 討論: ‘ 經濟部智慧財產局員工消費合作社印製 此等硏究的結果確定於調和物中添加黃原膠可改良以 此等調和物來餵食之嬰兒的耐受性。饌食調和物B、C及D ( 具有黃原膠W受性改良劑)之嬰兒比起餵食對照組調和物之 嬰兒一般而言排便較少(表II)。確認結果則發現到:相較於饌 食對照組調和物的嬰兒,餵食調和物B、C及D的嬰兒之雙親 們認爲嬰兒們有排便過多現象的天數較少。此外,相較於 饌食對照組調和物之該組,在餵食調和物B、C及D之群組中 由於對調和物有不耐受性而退出硏究之嬰兒的數目顯著地 較少。結果係示於表VI。饌食對照組調和物,即不含有耐 受性改良劑之調和物的小組中嬰兒退出率爲2 2 %。所以,相 較於該對照組,餵食調和物B、C及D之群組之嬰兒退出率的 降低(0-6%)在臨床上係十分驚人的。雖然納入此硏究的嬰兒 爲健康的嬰兒(已知對於完整蛋白質不具過敏性或敏感性), 在此所_到的改良耐受性的效果應該也可以在對於完整蛋 白質過敏或敏感之嬰兒,對於目前水解物調和物顯示不耐 受性症狀之嬰兒及一歲以上具不耐受性症狀之孩童的身上 產生效果‘。 實施例2 一粉末狀調和物係藉著將約6870磅玉米麥芽糖糊精, 本纸張尺度適用中國國家標準(CNS ) 規格(210X 297公釐) -20- 1241167 A7 B7 五、發明説明( 3095磅蔗糖,24.4公斤氯化鎂,54.9公斤檸檬酸鉀,17.8公 斤氯化鈉,114.5公斤磷酸鈣,25.5碳酸鈣,16.4公斤氯化鉀 及13· 7公斤碘化鉀於160°F溶於水而製成水溶液來製備。製 備水溶液所用的水量可基於所用之特殊製造設備而作最適 當的調整。將此溶液與第二種溶液混在一起以形成漿液, 該第二種溶液含有1 9 1 1磅M C T油,1 3 0 · 6公斤酒石酸二乙醯 酯之甘油單酯或甘油二酯,26.1公斤之甘油單酯及甘油二酯 5 2 0 2 0磅高油酸紅花油,1 · 1磅生育酚混合物,丨6 1 3磅豆油 ,2。1公斤棕櫚酸抗壞血酸酯及3 · 2公斤之維生素預混物,該 預混物含有維生素Α棕櫚酸酯,維生素Ε醋酸酯,維生素Κ, 及維生素D3。此漿液在溫度68至74°C下混合至少30分鐘而 最久兩小時。此漿液以lOQOpsi來乳化,透過二階均質器以
2500psi/500psi均質化,且透過板式熱交換器來冷卻到約4°C 。將含有游離胺基酸、水溶性維生素及微量礦物質之溶液 加到加工過的漿液中。該漿液被加熱到74.4到85°C至少16秒 且被噴乾以獲得濕度約1 . 5 %之粉末。將噴乾粉末與約3 4 3 0 磅酪蛋白·水解物及51.2公斤黃原膠乾混在一起。 實施例3 一粉末狀調和物係藉著將約6870磅玉米麥芽糖糊精, 3095磅蔗糖,24.4公斤氯化鎂,54.9公斤檸檬酸鉀,17.8公 斤氯化鈉’ 114.5公斤磷酸鈣,25.5碳酸鈣,16.4公斤氯化鉀 及13.7公斤碘化鉀於丨6〇卞溶於水而製成水溶液來製備。製 備水溶液所用的水量可基於所用之特殊製造設備而作最適 本纸張尺度適用中國國家標準(CG774規格(210X 297公釐) " -21 - --------II (請先閱讀背面之注意事項再填寫本頁) 、11 · 經濟部智慈財產局員工消費合作社印製 1241167 A7 _B7 _____ 五、發明説明(1与 當的調整。將此溶液與第二種溶液混在一起以形成漿液, 該第二種溶液含有1911磅MCT油,130.6公斤酒石酸二乙醯 酯之甘油單酯或甘油二酯,2 6.1公斤之甘油單酯及甘油二酯 ,2020磅,高油酸紅花油,1.1磅生育酚混合物,16 13磅豆油 ,2.1公斤棕櫚酸抗壞血酸酯及3.2公斤之維生素預混物,該 預混物含有維生素A棕櫚酸酯,維生素E醋酸酯,維生素K, 及維生素D3。此漿液在溫度68至74 °C下混合至少30分鐘而 最久兩小時。此漿液以lOOOpsi來乳化,透過二階均質器以 2500psi/500psi均質化,且透過板式熱交換器來冷卻到約 。將約3430磅酪蛋白水解物於溫度68-74°C下混於水中至少 3 0分鐘最久達2小時。此獎液以1 〇〇〇psi來乳化,透過二階均 質器以25 00pS1/5 00psi均質化,且透過板式熱交換器來冷卻 到約4°C且被加到醣類/脂肪/脂質混合物中。將含有游離胺 基酸、水溶性維生素及微量礦物質之溶液加到加工過的漿 液中。該發液被加熱到7 4.4到8 5 °C至少1 6秒且被噴乾以獲得 濕度約1 · 5 %之粉末。將噴乾粉末與約5 1.2公斤黃原膠乾混在 一起。 實施例4 ' 一粉末狀調和物係藉著將約6870磅玉米麥芽糖糊精, 3 0 95磅蔗糖,24.4公斤氯化鎂,54.9公斤檸檬酸鉀,17.8公 斤氯化鈉,1 1 4 · 5公斤磷酸鈣,2 5.5碳酸鈣,1 6 · 4公斤氯化鉀 及1 3 · 7公斤碘化鉀於1 6 0 °F溶於水而製成水溶液來製備。製 備水溶液所用的水量可基於所用之特殊製造設備而作最適 紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐)~~~~ -22- (請先閲讀背面之注意事項再填寫本頁) - 訂 經濟部智慧財產局員工消費合作社印製 1241167 A7 B7 五、發明説明( (請先閲讀背面之注意事項再填寫本頁) 當的調整。將此溶液與第二種溶液混在一起,該第二種溶 液含有1911磅MCT油,130.6公斤酒石酸二乙醯酯之甘油單 酯或甘油二酯,26.1公斤之甘油單酯及甘油二酯,2020磅高 油酸紅花油,1。1磅生育酚混合物,1 6 1 3磅豆油,2.1公斤棕 櫚酸抗壞血酸酯及3.2公斤之維生素預混物,該預混物含有 維生素A棕櫚酸酯,維生素E醋酸酯,維生素K,及維生素 D3 ;以及黃原膠以形成漿液。此漿液在溫度68至74. °C下混 合至少30分鐘而最久兩小時。此漿液以lOOOpsi來乳化,透 過二階均質器以25 00psi/500psi均質化,且透過板式熱交換 器來冷卻到約4°C。將約3430磅酪蛋白水解物於溫度68-74°C 下混於水中至少30分鐘最久達2小時。此漿液以lOOOpsi來乳 化,透過二階均質器以25 00psi/5 00psi均質化,' 且透過板式 熱交換器來冷卻到約4 °C且被加到醣類/脂肪/脂質混合物中 。將含有游離胺基酸、水溶性維生素及微量礦物質之溶液 加到加工過的漿液中。該漿液被加熱到74.4到8 5 °C至少1 6秒 且被噴乾以獲得濕度約1.5%之粉末。 實施例5 經濟部智M財產局員工消費合作社印製 --粉k狀調和物係藉著將約6870磅稻麥芽糖糊精, 3 095磅蔗糖,24.4公斤氯化鎂,54.9公斤檸檬酸鉀,17.8公 斤氯化鈉,114.5公斤磷酸鈣,25.5碳酸鈣,16.4公斤氯化鉀 及1 3 · 7公厅碘化鉀於1 6 0 °F溶於水而製成水溶液來製備。將 此溶液與第二種溶液混在一起以形成漿液,該第二種溶液 含有1911磅MCT油,130.6公斤酒石酸二乙醯酯之甘油單酯 -23- 本纸張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 1241167 __^_B7__ 五、發明説明(21) 或甘油二酯,26.1公斤之甘油單酯及甘油二酯,2020磅高油 酸紅花油,1.1磅生育酚混合物,1613磅豆油,2.1公斤棕櫚 酸抗壞血酸酯及3.2公斤之維生素預混物,該預混物含有維 生素A棕櫚酸酯,維生素E醋酸酯,維生素K,及維生素D3 。此漿液在溫度68至74 °C下混合至少30分鐘而最久兩小時 。此漿液以lOOOpsi來乳化,透過二階均質器以2500ρδ1/500ρ S1均質化,且透過板式熱交換器來冷卻到約4°c。將含有水 溶性維生素及微量礦物質之溶液加到加工過的漿液中。該 漿液被加熱到74.4到85°C至少16秒且被噴乾以獲得濕度約 1 .5%之粉末。將噴乾粉末與約343 0磅酪蛋白水解物,游離 胺基酸,41.2公斤角豆膠及51.2公斤黃原膠乾混在一起。 雖然本發明在此參考特殊具體例來作說明,應了解地 其並不意圖將本發明限制在所揭露的特定形式中。相反地 ’本發明意圖涵蓋所有具有本發明之精神且屬於本發明範 圍內之修正及替換形式。 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(2丨0>< 297公釐) -24 - 經濟部智慧財產局員工消費合作社印製 1241167 A7 B7 五、發明説明(2$
表I 於每100仟卡.,每10 0克粉末及每公升(以餵食濃度表示)中糖 類,脂質及蛋白質量之範圍 營養素(克) 範圍 每1〇0 仟卡 每100克粉末 每公升 (以餵食濃度表示) 糖類 最廣 8-16 30-90 53-107 較佳 9.4-12.3 48-59 64-83 脂質 最廣 3-6 15-30 22-40 .較佳 4.7-5.6 22-28 32-38 蛋白質 最廣 1.8-3.3 8-17 12-22 較佳 2.4-3.3 11-17 16-22 I -- (請先閱讀背面之注意事項再填寫本頁) 、11 鮮 本纸張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) -25- 1241167 A7 B7 經濟部智E財產局員工消費合作社印製 五、發明説明(约
表II 對照組及調和物B ,C及D*之營養素含量 營養素1 每公升 每100仟卡 每lOOg粉末 蛋白質(g) 18.6 2.7 5 13.9 脂肪(g) 37.5 5.55 28.1 糖類(g) 73 10.8 54.6 金丐(m g) 710 105 531 磷(mg) 507 75 379 鎂(m g) 51 7.5 38.1 鐵(mg): 12.2 1.8 9.1 鋅(m g) 5 0.74 3.7 锰(meg) 34 5 25 銅(ITlCg) 500 74 374 W (meg) 100 14.8 75 鈉(mg.) 297 43.9 222 鉀(m g) 800 118.3 598 氯(m g) ·’ 541 80 405 iB (meg) 16 2.4 12 (請先閱讀背面之注意事項再填寫本頁) ^紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) -26- 1241167 A7 ______ B7 五、發明説明(2冷 營養素1 B--—-- 每公升 每100仟卡 每1 00g粉末 維生素A(IU) 2?2〇〇 325 1,646 維生素D(IU) 400 59 299 維生素E(IU) 20.8 3.1 15.6 維生素K!(IU) 101 14.9 75.5 噻胺(m c g) 580 86 434 核黃素 600 89 449 維生素B-6(mcg) 530 78 396 維生素B -1 2 3 0.44 2.24 (meg) 蘇酸(m g) 9 1.33 6.73 葉酸(meg) 100 14.8 74.8 泛酸(m g). 5 0.74 3.74 生物素(m.cg) 30 4.4 22.4 維生素C〇ng) 90 13.3 67.3 膽驗(mg) 圓 :·. ———— 53 7.8 39.6 肌醇(mg) ; 30 4.4 22.4 (請先閲讀背面之注意事項再填寫本頁} 經濟部智慧財產局員工消費合作社印製 *除了醣類係以蛋白質及脂質在最低份量時該醣類之最 高份量來表示以外,其它數據均爲其最低份量數値。 對照組調和物成份:玉米麥芽糖糊精、酪蛋白水解物(用 酶水解過且用木炭處理過)、蔗糖、高油酸紅花油、分餾椰 子油(中等鏈長甘油三酯)、豆油、二乙醯基酒石酸酯之甘油 • 4 本紙張尺度適用中國國家標準(CMS ) A4規格(210X 297公釐) -27- 1241167 A7 ____B7 五、發明説明(2$ (請先閱讀背面之注意事項再填寫本頁) 單酯及甘'油二酯、磷酸鈣、檸檬酸鉀、甘油單酯及二酯、 碳酸鈣、氯化鎂 '抗壞血酸、L-胱胺酸二鹽酸鹽、氯化鈉 、氯化鉀、L-酪胺酸酸、氯化膽鹼、L-色胺酸、硫酸亞鐵、 牛磺酸' m-肌醇、抗壞血酸棕櫚酸酯、維生素E醋酸酯、硫 酸鋅、生育酚混合物、L -肉毒鹼、菸醯胺、泛酸鈣、硫酸 銅、維生素A棕櫚酸酯、噻胺鹽酸鹽、核黃素、吡哆醇鹽酸 鹽、葉酸、碘化鉀' 硫酸錳、葉綠醌、生物素、亞硒酸鈉 、維生素D3、氰鈷胺素。 經濟部智慧財產局員工消費合作社印製 調和物B、C及D成份:玉米麥芽糖糊精、酪蛋白水解物( 用酶水解.過且用木炭處理過)、蔗糖、高油酸紅花油、分餾 椰子油(中等鏈長甘油三酯)、豆油、二乙醯基酒石酸酯之甘 油單酯及甘油二酯、磷酸鈣、檸檬酸鉀、黃原膠、甘油單 酯及二酯、碳酸鈣、氯化鎂、抗壞血酸、L-胱胺酸二鹽酸 鹽、氯化·鈉、氯化鉀、L-酪胺酸酸、氯化膽鹼、L-色胺酸、 硫酸亞鐵、牛磺酸、m-肌醇、抗壞血酸棕櫚酸酯、維生素E 醋酸酯、硫酸鋅、生育酚混合物、L-肉毒鹼、菸醯胺、泛 酸鈣、硫酸銅、維生素A棕櫚酸酯、噻胺鹽酸鹽、核黃素' 吡哆醇鹽酸鹽、葉酸、碘化鉀、硫酸錳、葉綠醌、生物素 、亞硒酸鈉、維生素D3、氰鈷胺素。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) -28 - 1241167 A7 B7 五、發明説明(2$
表IIA 於對照組及調合物B,C及D中黃原膠之份量(MG) 調和物 每公升 每100仟卡 每100g粉末 A 0 0 0 B 500 74 374 C 1,000 148 748 D· 1,500 222 1,122 (請先閱讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 本纸張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) -29 - 1241167 A7 B7
五、發明説明(· 2》 表III 經濟部智慧財產局員工消費合作社印製
(請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國.國家標準(CNS ) A4規格ί 2】0X 297公釐) 於基線及實驗期間每日排便次數,糞便稠度平均等級,及水樣 便,鬆散/泥狀便,軟便及成形糞便之丨匕率_- .. ^ 實驗 -3〇 - 經濟部智慧財產局員工消費合作社印製 1241167 A7 B7 五、發明説明(2弓 表111(續) 參數 組/調和物 基線 (第1-7天) 實驗 (第1-8天) %軟便 對照組 45.4土 5.4 22.6± 4.9 B 38.0土 5.4 25·4± 6.3 C 31。6土 5.0 33.8± 7.5 D 31.8± 4.0 37.0± 5_8 %成形糞便 對照組 5.7土 1.9 6.3± 3.2 B 5.3± 1.9 0.0± 0.0 C 5.8± 2.7 2.2± 1.4 D 3.4± 1.2 5.4± 2.3 1 平均値±該平均値之標準差 2 1=氷樣,2 =鬆散/泥狀,3 =軟便,4 =成形糞便,5 =硬度 本纸張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
1241167 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明説明(2自
表IV 在基線或實驗期間每日餵食次數,平均攝取量,及具有溢奶, 吐奶,溢奶及吐奶現象之餵食比率1 參數 組/調和物 基線 (第1-7天) 實驗 (第1-8天) 饌食次數/曰 對照組 7.5± 0.2 7.3± 0.3 B 7.4± 0.2 7.3土 0.3 C 7.4± 0.3 7·1± 0.3 D 7.2± 0.2 6.9± 0.2 平均攝取量(m 1 /日) 對照組 524± 19 568± 26 B 556± 28 624± 32 C 525土 21 605± 24 D 551± 26 608± 21 有溢奶現象之餵食% 對照組 11.1± 2.0 13.3± 3.5 B 17.0± 3.1 11.7± 2.1 C 23·8± 4.3 15·0± 4.2 D 11.5± 2.2 9·0± 1.8 (請先閱讀背面之注意事項再填寫本頁) 本纸張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -32- 1241167 A7 B7 五、發明説明(的 表IV(續)' 參數 組/調和物 基線 (第1-7天) 實驗 (第1-8天) 有任何吐奶現象之主 體% 對照組 8.2土 2.9 2.0± 1.0 B 4.1± 1.4 3.9± 2.9 C 7.3± 2.6 3.6± 2.0 D 4.8土 1.6 2.6± 1.0 具有溢奶或吐奶現象 之餵食% 對照組 19.3± 3.5 15.3± 3.5 B 21·0± 3.8 15.6土 3.3 C 31.2土 5·1 18.6± 4.5 D 16.3± 3.2 11.5± 2.3 1 平均値d:該平均値之標準差 I #丨1 (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中_國象標準(CNS ) A4規格(2:10X 297公釐) -33- 1241167 A7 B7 五、發明説明(· 31) 於基線及實驗期間嬰兒體重增加情形 參數 組/調和物 基線 (第1-7天) 實驗 (第8-14天) 體重增加(克_/日) 對照組2 30.2± 2.7 31.1± 2.9 B3 33.6± 2.6 34.4土 2.1 C4 29·3± 2.8 30.9± 2.8 D5 26.6± 2.4 34.1± 2.7 1 1 平均値±該平均値標準差 2 嬰兒數目:44名於基線組,35名於實驗組。 3 嬰兒數目:43名於基線組,35名於實驗組。 4 嬰兒數目:39名於基線組,28名於實驗組。 5 嬰兒數目:44名於基線組,36名於實驗組。 {請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(21〇Χ 297公釐) -34- 1241167 A7 B7 五、發明説明(珀
表VI 餵食後主體結果(11=182) 離開狀態 調和物 對照組 B C D 成功地完·:成實驗 29 33 28 35 提早退出.](第8-14天) 8 2 0 2 基線期退··出(第1-7天) 9 11 17 8 退出比率2 22 6 〇 5 總數 46 46 45 45 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1 除了 一名在1 500組之嬰兒以外,其它所有嬰兒都因爲對 調和物之不耐受性或由於雙親不滿意而提早退出硏究 2 比率=[提早退出者(第8-14天)/[成功完成實驗者+於基 線期退出者(第1-7天)]x 100 本紙張尺度適用中國國家標準(CNS ) Λ4規格(210X 297公釐) -35-
Claims (1)
- [241167 m. .A 8 •68 —C8 D8 .......... ..... .........、·............... ^、申請專利範圍 附件2 A : 弟9 Ο 1 Ο 2 2 6 5 5虎專利申請案 中文申請專利範圍替換本 民國94年5月24 日修正 1· 一種嬰幼兒調和物,其於每1 0 〇仟卡中含有約8到約1 6 克醣類,約3克到約6克脂質,約1.8克到約3.3克蛋白質及含 有約74毫克到約222毫克黃原膠之耐受性改良劑。 2.如申請專利範圍第1項之嬰幼兒調和物,其中該黃原 膠含量爲約111到約148毫克。 3 .如申請專利範圍第1項之嬰幼兒調和物,其中該醣類 含量爲約9.4克到約12.3克。 4.如申請專利範圍第1項之嬰幼兒調和物,其中該脂質 含量爲約4.7克到約5.6克。 5 .如申請專利範圍第1項之嬰幼兒調和物,其中該蛋白 質含量爲約2.4克到約3.3克。 6.如申請專利範圍第1項之嬰幼兒調和物,進一步含有 多種維生素及礦物質。 7 .如申請專利範圍第1項之嬰幼兒調和物,其中該維生 素及礦物質係選自由鈣、磷、鈉、氯、鎂、錳、鐵、銅、 鋅、硒、碘及維生素A、Ε、C、D、Κ及Β群,及其混合物所 組成之群組。 8 ·如申請專利範圍第1項之嬰幼兒調和物,其中該脂質 係選自由椰子油、丑油、玉米油、橄橫油、紅花油、高油 酸紅花油、MCT油(中等鏈長甘油三酯)、葵花油、高油酸葵 花油、棕櫚油、棕櫚仁油、低芥酸含量之油菜油、花生四 Μ氏張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -- (請先閲讀背面之注意事項再填寫本頁) 、11 •10 經濟部智慧財產局員工消費合作社印製 1241167 A8 B8 C8 _ D8 六、申請專利範圍 烯酸及二十二碳六烯酸之脂質來源,及其混合物所組成之 群組。 (請先閱讀背面之注意事項再填寫本頁) 9 .如申請專利範圍第1項之嬰幼兒調和物,其中該蛋白 質包括完整蛋白質,其係選自大豆爲主之蛋白質、乳汁爲 主之蛋白質、酪蛋白蛋白質、乳淸蛋白質、米蛋白質、牛 肉膠原蛋白、豌豆蛋白質、馬鈴薯蛋白質及其混合物所成 之群組。 1 0.如申請專利範圍第1項之嬰幼兒調和物,其中該蛋白 質包括水解過之蛋白質,其係選自大豆蛋白質水解物、酪 蛋白蛋白質水解物、乳淸蛋白質水解物、米蛋白質水解物 、馬鈴薯蛋白質水解物、魚蛋白質水解物、卵白蛋白質水 解物、明膠蛋白質水解物、動物及植物蛋白質水解物的組 合,及其混合物所組成之群組。 1 1 ·如申請專利範圍第丨項之嬰幼兒調和物,其中該蛋白 質包括游離胺基酸,其係選自色胺酸、酪胺酸、胱胺酸、 牛磺酸、L-甲硫胺酸、L_精胺酸及肉毒鹼及其混合物所組成 之群組。 經濟部智慧財產局員工消費合作社印製 12·如申請專利範圍第丨項之嬰幼兒調和物,其中該醣類 係選自水解過的、完整的、天然的及/或化學修改過的澱粉 來源,其可來自玉米、樹薯、米或馬鈴薯糯質或非糯質的 形式;以及糖類如葡萄糖、果糖、乳糖、蔗糖、麥芽糖, 高果糖量玉米糖漿、及其混合物所組成之群組。 1 3 .如申請專利範圍第1項之嬰幼兒調和物,進一步含有 一安定劑,其係選自阿拉伯膠、印度膠、梧桐膠、黃蓍膠 -2- 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 1241167 A8 B8 C8 D8 六、申請專利範圍 、洋菜、叉纖維聚糖(furceUai.an)、瓜爾膠(guar gum)、傑 倫膠(gel lan gum)、角豆膠、果膠、低甲氧果膠、明膠、微 晶纖維素、C M C (竣甲基纖維素鈉)、甲基纖維素、建丙基甲 基纖維素、羥丙基纖維素、葡聚糖、及其混合物所組成之 群組。 14. 一種嬰幼兒調和物,呈粉末形式,其於每1〇〇克粉末 中含有約30到約90克醣類,約15到約30克脂質,約8到約17 克蛋白質,及約374到約1125毫克黃原膠。 15. 如申請專利範圍第14項之嬰幼兒調和物,其中該黃 原膠含量爲約565到約750毫克。 1 6 ·如申請專利範圍第1 4項之嬰幼兒調和物,其中該醣 類含量爲約48到約59克。 17. 如申請專利範圍第14項之嬰幼兒調和物,其中該脂 質含量爲約22到約28克。 18. 如申請專利範圍第14項之嬰幼兒調和物’其中該蛋 白質含量爲約11到約1 7克。 19·如申請專利範圍第4項之嬰幼兒調和物’進一步含有 多種維生素及礦物質。 20·如申請專利範圍第19項之嬰幼兒調和物’其中該維 生素及礦物質係選自由鈣、磷、鈉、氯、鎂、猛、鐵、銅 、鋅、硒、碘及維生素A、Ε、C、D、Κ及Β群,及其混合物 所組成之群組。 2 1 ·如申請專利範圍第1 4項之嬰幼兒調和物’其中該脂 質係選自由椰子油、豆油、玉米油、橄欖油、紅花油、高 (請先聞讀背面之注意事項再填寫本頁) 、11 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X29?公釐) -3- 1241167 A8 B8 C8 D8 六、申請專利範圍 (請先聞讀背面之注意事項再填寫本頁) 油酸紅花油、MCT油(中等鏈長甘油三酯)、葵花油、高油酸 葵化油、b櫚油、棕櫚仁油、低芥酸含量之油菜油(c a n 0 h ◦ Π )、花生四儲酸及二十二碳六烯酸之脂質來源,及其混 合物所組成之群組。 22·如申請專利範圍第14項之嬰幼兒調和物,其中該蛋 白質包括完整蛋白質,其係選自大豆爲主之蛋白質、乳汁 爲主之蛋白質、酪蛋白蛋白質、乳淸蛋白質、米蛋白質、 牛肉膠原蛋白、豌豆蛋白質、馬鈴薯蛋白質及其混合物所 成之群組。 23·如申請專利範圍第14項之嬰幼兒調和物,其中該蛋 白質包括水解過之蛋白質,其係選自大豆蛋白質水解物、 酪蛋白蛋白質水解物、乳淸蛋白質水解物、米蛋白質水解 物、馬鈴薯蛋白質水解物、魚蛋白質水解物、卵白蛋白質 水解物、明膠蛋白質水解物、動物及植物蛋白質水解物的 組合’及其混合物所組成之群組。 經濟部智慧財產局員工消費合作社印製 2 4 ·如申請專利範圍第1 4項之嬰幼兒調和物,其中該蛋 白質包括游離胺基酸,其係選自色胺酸、酪胺酸、胱胺酸 、牛磺酸、L-甲硫胺酸、L-精胺酸及肉毒鹼及其混合物所組 成之群組。 2 5 ·如申請專利範圍第1 4項之嬰幼兒調和物,其中該醣 類係選自水解過的、完整的、天然的及/或化學修改過的源 粉來源’其可來自玉米 '樹馨、米或馬鈴馨懦質或非糯晳 的形式;以及糖類如蔔萄糖、果糖、乳糖、蔗糖、麥芽糖 ,高果糖量玉米糖漿、及其混合物所組成之群組。 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) ~ 1241167 A8 B8 C8 D8 ______ 六、申請專利範圍 26.如申請專利範圍第14項之嬰幼兒調和物’進一步含 有一安定劑,其係選自阿拉伯膠、印度膠、梧桐膠、黃蓍 膠、洋菜、叉纖維聚糖(furcellaran)、瓜爾膠(guai· gum)、傑 倫膠(gellan gum)、角豆膠、果膠 '低甲氧果膠、明膠、微 晶纖維素、CMC(羧甲基纖維素鈉)、甲基纖維素、羥丙基甲 基纖維素、羥丙基纖維素、葡聚糖、及其混合物所組成之 群組。 (請先閲讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) _ 5 _
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/498,350 US6365218B1 (en) | 2000-02-04 | 2000-02-04 | Pediatric formula and methods for providing nutrition and improving tolerance |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI241167B true TWI241167B (en) | 2005-10-11 |
Family
ID=23980707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW090102265A TWI241167B (en) | 2000-02-04 | 2001-02-02 | Improved pediatric formula and methods for providing nutrition and improving tolerance |
Country Status (28)
Country | Link |
---|---|
US (2) | US6365218B1 (zh) |
EP (1) | EP1251750B1 (zh) |
JP (1) | JP2003521501A (zh) |
KR (1) | KR100767202B1 (zh) |
CN (1) | CN1400870A (zh) |
AT (1) | ATE321462T1 (zh) |
AU (1) | AU780438B2 (zh) |
BG (1) | BG107019A (zh) |
BR (1) | BR0106681A (zh) |
CA (1) | CA2396148C (zh) |
CY (1) | CY1108033T1 (zh) |
CZ (1) | CZ20022743A3 (zh) |
DE (1) | DE60118387T2 (zh) |
DK (1) | DK1251750T3 (zh) |
ES (1) | ES2261432T3 (zh) |
HK (1) | HK1050983B (zh) |
HU (1) | HUP0204382A3 (zh) |
IL (1) | IL150326A (zh) |
MX (1) | MXPA02006938A (zh) |
NO (1) | NO20023684L (zh) |
NZ (1) | NZ519695A (zh) |
PL (1) | PL357134A1 (zh) |
PT (1) | PT1251750E (zh) |
SI (1) | SI21018A (zh) |
SK (1) | SK12562002A3 (zh) |
TR (1) | TR200201921T2 (zh) |
TW (1) | TWI241167B (zh) |
WO (1) | WO2001056406A1 (zh) |
Families Citing this family (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6365218B1 (en) * | 2000-02-04 | 2002-04-02 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
SE520688C2 (sv) * | 2000-04-11 | 2003-08-12 | Bone Support Ab | Ett injicerbart ersättningsmaterial för benmineral |
SE517168C2 (sv) * | 2000-07-17 | 2002-04-23 | Bone Support Ab | En komposition för ett injicerbart ersättningsmaterial för benmineral |
US6716466B2 (en) * | 2001-01-17 | 2004-04-06 | Nestec S.A. | Balanced food powder composition |
US20040121044A1 (en) * | 2001-03-14 | 2004-06-24 | John Tiano | Nutritional product with high protein, low carbohydrate content and good physical stability |
US6808736B2 (en) * | 2001-06-07 | 2004-10-26 | Nestec S.A. | Soy hydrolysate based nutritional formulations |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US20060039958A1 (en) * | 2003-05-28 | 2006-02-23 | Monosolrx, Llc. | Multi-layer films having uniform content |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US20030099753A1 (en) * | 2001-11-20 | 2003-05-29 | Yang Baokang | Juice based beverage compositions |
SE522098C2 (sv) * | 2001-12-20 | 2004-01-13 | Bone Support Ab | Ett nytt benmineralsubstitut |
US8367098B2 (en) | 2002-04-30 | 2013-02-05 | The Population Council, Inc. | Unique combinations of antimicrobial compositions |
US7070825B2 (en) * | 2002-09-10 | 2006-07-04 | Abbott Laboratories | Infant formula |
SE0300620D0 (sv) * | 2003-03-05 | 2003-03-05 | Bone Support Ab | A new bone substitute composition |
US20040214791A1 (en) * | 2003-04-25 | 2004-10-28 | Nancy Auestad | High lactose infant nutrition formula |
DE10339180A1 (de) * | 2003-08-21 | 2005-03-24 | Deutsche Gelatine-Fabriken Stoess Ag | Kollagenhydrolysat |
DE602004005348T2 (de) * | 2003-09-10 | 2007-07-12 | Unilever N.V. | Nahrungsmittelzusammensetzung |
NO319624B1 (no) * | 2003-09-15 | 2005-09-05 | Trouw Internat Bv | Fiskefôr for laksefisk i ferskvann og anvendelse av slikt fôr. |
SE0302983D0 (sv) * | 2003-11-11 | 2003-11-11 | Bone Support Ab | Anordning för att förse spongiöst ben med benersättnings- och/eller benförstärkningsmaterial och förfarande i samband därmed |
US20050276762A1 (en) * | 2004-06-15 | 2005-12-15 | Tapas Das | Topical compositions containing 5'-adenosine-diphosphate ribose |
SE527528C2 (sv) * | 2004-06-22 | 2006-04-04 | Bone Support Ab | Anordning för framställning av härdbar massa samt användning av anordningen |
EP2335921A1 (en) | 2004-09-30 | 2011-06-22 | MonoSolRX, LLC | Multi-layer films |
US20060251634A1 (en) | 2005-05-06 | 2006-11-09 | Ho-Jin Kang | Method of improving immune function in mammals using lactobacillus strains with certain lipids |
WO2006130027A1 (en) * | 2005-05-31 | 2006-12-07 | Santos Ma Joyce Bedelia B | Aqueous oral liquid vitamin supplements containing stabilized vitamin c and metal ions |
US20060286208A1 (en) * | 2005-06-01 | 2006-12-21 | Nagendra Rangavajla | Methods for producing protein partial hydrolysates and infant formulas containing the same |
US7618669B2 (en) * | 2005-06-01 | 2009-11-17 | Mead Johnson Nutrition Company | Low-lactose partially hydrolyzed infant formula |
US7829126B2 (en) | 2005-10-26 | 2010-11-09 | Abbott Laboratories | Infant formulas containing docosahexaenoic acid and lutein |
US20070166354A1 (en) | 2005-10-26 | 2007-07-19 | Bridget Barrett-Reis | Method of reducing the risk of retinopathy of prematurity in preterm infants |
US20070134395A1 (en) * | 2005-12-13 | 2007-06-14 | Hodges Everett L | Method of reducing manganese in defatted soy isolate |
US20070166411A1 (en) * | 2005-12-16 | 2007-07-19 | Bristol-Myers Squibb Company | Nutritional supplement containing long-chain polyunsaturated fatty acids |
US7691547B2 (en) * | 2006-03-16 | 2010-04-06 | Microtome Precision, Inc. | Reticle containing structures for sensing electric field exposure and a method for its use |
US20070281054A1 (en) * | 2006-05-31 | 2007-12-06 | Abbott Laboratories | Organic powder nutritional formula containing select carbohydrate combinations |
EP1867237A1 (en) * | 2006-06-15 | 2007-12-19 | Nestec S.A. | Hypoallergenic Egg |
US20080026105A1 (en) * | 2006-07-28 | 2008-01-31 | Bristol-Myers Squibb Company | Nutritional formulations containing octenyl succinate anhydride-modified tapioca starch |
US8722120B2 (en) * | 2006-08-02 | 2014-05-13 | Mead Johnson Nutrition Company | Amino acid-based nutritional formulations |
CN100463681C (zh) * | 2006-10-24 | 2009-02-25 | 北京紫竹药业有限公司 | 一种治疗干眼症的人工泪液 |
CA2705145A1 (en) | 2007-11-07 | 2009-05-14 | Mead Johnson Nutrition Company | Method for decreasing bitterness and improving taste of protein-free and hydrolyzed infant formulas |
US8329642B1 (en) | 2007-11-14 | 2012-12-11 | Gans Eugene H | Formula and method to enhance external physiognomy |
PL2214510T3 (pl) * | 2007-11-20 | 2018-01-31 | Nutricia Nv | Obróbka proszku gumy karobowej |
US9131721B2 (en) * | 2007-12-04 | 2015-09-15 | Nestec S.A. | Gut microbiota in infants |
US8361534B2 (en) * | 2007-12-20 | 2013-01-29 | Abbott Laboratories | Stable nutritional powder |
NZ585619A (en) | 2007-12-20 | 2012-06-29 | Abbott Lab | Nutritional powder composition comprising carbohydrate, lipid, hydrolysed whey and intact protein |
US20100068346A1 (en) * | 2008-09-16 | 2010-03-18 | Hodges Everett L | Infant formula |
AU2009306497B2 (en) * | 2008-10-20 | 2015-01-29 | Société des Produits Nestlé S.A. | Nutritional composition with anti-regurgitation properties |
IT1392084B1 (it) * | 2008-12-12 | 2012-02-09 | Marzullo | Composizione immuno-nutrizionale |
ES2458817T5 (es) † | 2009-03-02 | 2017-09-11 | Roquette Freres | Polvo granulado de leche vegetal, procedimiento de obtención de leche vegetal y sus utilizaciones |
WO2010126353A1 (en) * | 2009-04-27 | 2010-11-04 | N.V. Nutricia | Pea-based protein mixture and use thereof in a liquid nutritional composition suitable for enteral feeding |
TW201112967A (en) * | 2009-09-16 | 2011-04-16 | Abbott Lab | Dryblended nutritional powders |
TW201121431A (en) * | 2009-12-01 | 2011-07-01 | Abbott Lab | Soy protein-based nutritional formula with superior stability |
TWI492744B (zh) * | 2009-12-04 | 2015-07-21 | Abbott Lab | 使用類胡蘿蔔素調節早產兒發炎症之方法 |
BR112012018321A2 (pt) * | 2009-12-22 | 2019-09-24 | Nestec Sa | composições nutricionais e métodos para otimizar o potencial ácido-básico dietético |
EP2525811B2 (en) * | 2010-01-19 | 2019-02-27 | Abbott Laboratories | A composition comprising lactobacillus rhamnosus hn001 and prebiotics for use in the treatment of allergic lung disease |
WO2011094548A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising hmb |
US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
SG182812A1 (en) | 2010-01-29 | 2012-09-27 | Abbott Lab | Nutritional emulsions comprising calcium hmb |
US9180137B2 (en) | 2010-02-09 | 2015-11-10 | Bone Support Ab | Preparation of bone cement compositions |
TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣hmb及可溶性蛋白質之實質上透明營養液 |
EP2397038A1 (en) | 2010-06-21 | 2011-12-21 | Abbott Laboratories | Early programming of brain function through soy protein feeding |
EP2404507A1 (en) * | 2010-07-08 | 2012-01-11 | Nestec S.A. | Array of age-tailored nutritional formula with optimum fat content |
WO2012009426A1 (en) | 2010-07-13 | 2012-01-19 | Abbott Laboratories | High tolerance infant formula including hydrolyzed protein |
EP2422629A1 (en) | 2010-08-23 | 2012-02-29 | Abbott Laboratories | Methods for enhancing cognition and/or memory using maltodextrins |
WO2012027287A1 (en) | 2010-08-24 | 2012-03-01 | Abbott Laboratories | Nutritional products including pea protein hydrolysates |
EP2608681B1 (en) | 2010-08-24 | 2015-09-16 | Abbott Laboratories | Nutritional products having improved organoleptic properties |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
FI123201B (fi) * | 2010-10-29 | 2012-12-14 | Valio Oy | Maitopohjainen tuote ja valmistusmenetelmä |
FR2968895B1 (fr) | 2010-12-17 | 2013-04-12 | United Pharmaceuticals | Composition anti-regurgitation et/ou anti-reflux gastro-oesophagien, preparation et utilisations |
CA2820960A1 (en) | 2010-12-29 | 2012-07-05 | Abbott Laboratories | Nutritional products including a novel fat system including monoglycerides |
BR112013016934A2 (pt) * | 2010-12-30 | 2019-09-24 | Abbott Lab | tolerância aumentada em uma fórmula infantil de baixas calorias |
US20140010912A1 (en) * | 2010-12-30 | 2014-01-09 | Abbott Laboratories | Low calorie infant formula with improved physical attributes |
WO2012092083A1 (en) * | 2010-12-30 | 2012-07-05 | Abbott Laboratories | Improved rate of protein digestion in a low calorie infant formula |
MX355780B (es) | 2010-12-31 | 2018-04-30 | Abbott Lab | Fórmula pediátrica sintética para estimular células nerviosas entéricas en el tracto gastrointestinal. |
MX352040B (es) | 2010-12-31 | 2017-11-07 | Abbott Lab | Formulaciones nutricionales que incluyen los oligosacaridos de leche humana y los acidos grasos poliinsaturados de cadena larga y usos de las mismas. |
EP3473257A1 (en) | 2010-12-31 | 2019-04-24 | Abbott Laboratories | Methods of using human milk oligosaccharides for improving airway respiratory health |
NZ611807A (en) | 2010-12-31 | 2015-02-27 | Abbott Lab | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
CA2822497C (en) | 2010-12-31 | 2020-07-28 | Abbott Laboratories | Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents |
NZ612386A (en) | 2010-12-31 | 2015-02-27 | Abbott Lab | Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota |
EP3510873A1 (en) | 2010-12-31 | 2019-07-17 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
CN110051676A (zh) | 2010-12-31 | 2019-07-26 | 雅培制药有限公司 | 用于调节炎症的人乳寡糖 |
WO2013012989A2 (en) | 2011-07-19 | 2013-01-24 | The Trustees Of Columbia University In The City Of New York | Method and system for production of hydrogen and carbon monoxide |
DK2734210T3 (en) | 2011-07-22 | 2018-01-22 | Abbott Lab | GALACTOOLIGOSACCHARIDES FOR THE PREVENTION OF DAMAGE TO AND / OR PROMOTION OF HEALING OF THE MAVE GAS CHANNEL |
MX2011007872A (es) | 2011-07-26 | 2013-01-29 | Nucitec Sa De Cv | Composicion nutrimental para niños que presentan reflujo, colico y/o estreñimiento. |
BR112014004772A2 (pt) | 2011-08-29 | 2017-03-21 | Abbott Lab | oligossacarídeos do leite humano para evitar danos e/ou promover a cura do trato gastrointestinal |
EP2757898B1 (en) | 2011-09-20 | 2015-10-21 | Abbott Laboratories | Powdered nutritional formulations including spray-dried plant protein |
WO2013101516A1 (en) | 2011-12-29 | 2013-07-04 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using extracted genomic dna |
EP2797438A2 (en) | 2011-12-29 | 2014-11-05 | Abbott Laboratories | Methods for reducing microbial contamination of dryblended powdered nutritional compositions |
US10849334B2 (en) | 2012-02-01 | 2020-12-01 | Koninklijke Douwe Egberts B.V. | Dairy mineral-fortified liquid dairy products and methods for making the dairy mineral-fortified liquid dairy products |
US20130196030A1 (en) | 2012-02-01 | 2013-08-01 | Anthony William Criezis | Dairy Products With Added Dairy Minerals And Methods Of Producing The Same |
WO2013133691A1 (en) * | 2012-03-09 | 2013-09-12 | N.V. Nutricia | Liquid nutritional composition comprising free amino acids |
MY168661A (en) | 2012-03-27 | 2018-11-28 | Abbott Lab | Methods for modulating cell-mediated immunity using human milk oligosaccharides |
IN2014DN07437A (zh) * | 2012-03-30 | 2015-04-24 | Otsuka Pharma Co Ltd | |
WO2013170189A1 (en) | 2012-05-11 | 2013-11-14 | Abbott Laboratories | Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow |
ES2572831T3 (es) | 2012-09-14 | 2016-06-02 | Abbott Laboratories | Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico |
EP2708147B1 (en) | 2012-09-14 | 2020-03-11 | Abbott Laboratories | Methods for increasing brain functionality using 2-fucosyl-lactose |
EP2708146A1 (en) | 2012-09-17 | 2014-03-19 | Abbott Laboratories, Inc. | Nutritional composition for pregnant women with a beneficial glucose and insulin profile |
WO2014078544A1 (en) | 2012-11-14 | 2014-05-22 | Abbott Laboratories | Compositions and methods for improving the long term safety of powdered infant formulas |
WO2014099904A1 (en) | 2012-12-17 | 2014-06-26 | Abbott Laboratories | Methods for enhancing motor function, enhancing functional status and mitigating muscle weakness in a subject |
WO2014100022A1 (en) | 2012-12-18 | 2014-06-26 | Abbott Laboratories | Dietary oligosaccharides to enhance learning and memory |
EP2745705A1 (en) | 2012-12-18 | 2014-06-25 | Abbott Laboratories | Nutritional use of human milk oligosaccharides |
ES2763958T3 (es) | 2012-12-18 | 2020-06-01 | Abbott Lab | Oligosacáridos de leche humana para mejorar los síntomas del estrés |
EP2934190B1 (en) | 2012-12-20 | 2018-12-12 | Abbott Laboratories | Nutritional formulations using human milk oligosaccharides for modulating inflammation |
EP2745708A1 (en) | 2012-12-24 | 2014-06-25 | Abbott Laboratories, Inc. | Antidepressant effect of ß-hydroxy-ß-methylbutyrate |
US10294107B2 (en) | 2013-02-20 | 2019-05-21 | Bone Support Ab | Setting of hardenable bone substitute |
US20140242216A1 (en) * | 2013-02-24 | 2014-08-28 | Mead Johnson Nutrition Company | Amino Acid And Protein Hydrolysate Based Formulas With A Stable Emulsion System |
SG11201507198PA (en) | 2013-03-12 | 2015-10-29 | Abbott Lab | Composition comprising a multifunctional viscosity modifying agent |
US20140271979A1 (en) * | 2013-03-15 | 2014-09-18 | Mead Johnson Nutrition Company | Anti-regurgitation nutritional composition |
US9844531B2 (en) | 2013-03-15 | 2017-12-19 | Abbott Laboratories | Methods of maintaining and improving muscle function |
CN105188417B (zh) | 2013-03-15 | 2017-08-08 | 雅培制药有限公司 | 包括β‑羟基‑β‑甲基丁酸钙、酪蛋白磷酸肽和蛋白质的营养组合物 |
FR3005392B1 (fr) * | 2013-05-07 | 2015-09-18 | United Pharmaceuticals | Composition anti-regurgitation preservant le transit intestinal |
US20160136192A1 (en) | 2013-06-10 | 2016-05-19 | Abbott Laboratories | Methods and compositions for enhancing cognitive performance |
WO2015048646A1 (en) | 2013-09-30 | 2015-04-02 | Abbott Laboratories | Protein powder |
IN2015DN03236A (zh) | 2013-10-11 | 2015-10-02 | Abbott Lab | |
WO2015077233A1 (en) | 2013-11-19 | 2015-05-28 | Abbott Laboratories | Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides |
EP2888950A1 (en) | 2013-12-24 | 2015-07-01 | Abbott Laboratories | Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment |
WO2015105981A2 (en) | 2014-01-09 | 2015-07-16 | Abbott Laboratories | Conditional essentiality of hmb |
MX2016013064A (es) | 2014-04-08 | 2017-01-26 | Abbott Lab | Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana. |
JP6718866B2 (ja) * | 2014-10-16 | 2020-07-08 | カーギル インコーポレイテッド | 直接圧縮性のエリスリトールの調製方法及びその使用 |
CN104489660A (zh) * | 2014-12-10 | 2015-04-08 | 常州兆阳光能科技有限公司 | 富硒低糖营养保健液 |
CN104544092A (zh) * | 2015-01-29 | 2015-04-29 | 王维义 | 一种亚麻籽油微囊粉及其制备工艺 |
WO2016126215A1 (en) * | 2015-02-03 | 2016-08-11 | Jirapinyo Pipop | Amino acid-based formula and production process thereof |
US10617700B1 (en) | 2016-02-26 | 2020-04-14 | Michelle Ann Toothman | Vitamin supplement compositions with enhanced bioavailability |
US10039805B1 (en) | 2016-02-26 | 2018-08-07 | Michelle Ann Toothman | Infant formulas having vitamin complexes with enhanced bioavailability |
US11122833B1 (en) | 2016-02-26 | 2021-09-21 | Michelle Ann Toothman | Infant formulas having vitamin complexes with enhanced bioavailability |
KR20230137362A (ko) | 2016-05-05 | 2023-10-04 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
SE542106C2 (en) * | 2016-08-26 | 2020-02-25 | Atif M Dabdoub | Dietary macro/micronutritional supplement for patients undergoing kidney dialysis |
AU2017327595B2 (en) * | 2016-09-13 | 2022-05-26 | Société des Produits Nestlé S.A. | Infant formula for cow's milk protein allergic infants |
US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
WO2020222248A1 (en) * | 2019-05-02 | 2020-11-05 | Nuflower Foods And Nutrition Private Limited | Ready to use food compositions and a method of making the same |
WO2020247225A1 (en) | 2019-06-07 | 2020-12-10 | Abbott Laboratories | Nutritional ingredient with flow and antifoam properties |
CA3171884A1 (en) | 2020-04-06 | 2021-10-14 | Abbott Laboratories | Nutritional formulations for modulating respiratory-induced cytokines |
KR102594730B1 (ko) * | 2020-09-21 | 2023-10-26 | 숙명여자대학교산학협력단 | 농축 유청 단백질 및 검류 혼합물로 이루어진 점도증진용 조성물 |
WO2022177965A1 (en) | 2021-02-16 | 2022-08-25 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin |
WO2022226311A1 (en) | 2021-04-23 | 2022-10-27 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and a designed lipid component for improving lung function |
WO2022266058A1 (en) | 2021-06-14 | 2022-12-22 | Abbott Laboratories | Methods and compositions for treating gas |
WO2023159093A1 (en) | 2022-02-16 | 2023-08-24 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin |
WO2024064327A1 (en) | 2022-09-22 | 2024-03-28 | Abbott Laboratories | Human milk oligosaccharides for enhancing blood-brain barrier function |
WO2024089059A1 (en) | 2022-10-25 | 2024-05-02 | N.V. Nutricia | Thickened formula for allergic infants |
WO2024089060A1 (en) * | 2022-10-25 | 2024-05-02 | N.V. Nutricia | Antiregurgitation formula |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4282262A (en) | 1980-03-04 | 1981-08-04 | General Mills, Inc. | Dairy based mixes for frozen desserts and method of preparation |
EP0045158A1 (en) | 1980-07-17 | 1982-02-03 | Merck & Co. Inc. | Process for thickening and stabilizing oil in water emulsions containing milk solids and emulsion stabilizer for use therein |
US4670268A (en) | 1985-01-29 | 1987-06-02 | Abbott Laboratories | Enteral nutritional hypoallergenic formula |
DD294404A5 (de) * | 1989-09-18 | 1991-10-02 | Akademie Der Wissenschaften,De | Verfahren zur herstellung von trockenmischungen fuer die zubereitung von fett-in-wasser-emulsionen fuer lebensmittelzwecke |
US5171602A (en) | 1990-06-13 | 1992-12-15 | Kraft General Foods, Inc. | Non-fat frozen dairy product |
CH681343A5 (zh) | 1990-10-26 | 1993-03-15 | Nestle Sa | |
US5256436A (en) | 1992-05-14 | 1993-10-26 | The Coca-Cola Company | Ready to serve frozen dessert for soft serve dispensing |
FR2699370B1 (fr) * | 1992-12-17 | 1995-01-13 | Cedilac Sa | Procédé pour la fabrication d'un lait infantile liquide prêt à l'emploi longue conservation et anti-régurgitation, et lait ainsi obtenu. |
US5472952A (en) | 1993-03-18 | 1995-12-05 | Bristol-Myers Squibb Company | Partially hydrolyzed pectin in nutritional compositions |
US5376396A (en) | 1993-04-27 | 1994-12-27 | Merck & Co., Inc. | Beverage stabilizing system and process thereof |
JP3510376B2 (ja) | 1995-03-16 | 2004-03-29 | 太陽化学株式会社 | 安定な乳飲料の製造法 |
US5609897A (en) | 1995-04-07 | 1997-03-11 | Abbott Laboratories | Powdered beverage concentrate or additive fortified with calcium and vitamin D |
US5597595A (en) | 1995-04-07 | 1997-01-28 | Abbott Laboratories | Low pH beverage fortified with calcium and vitamin D |
US5817351A (en) | 1995-04-07 | 1998-10-06 | Abbott Laboratories | Calcium fortified low pH beverage |
US6099871A (en) * | 1995-06-01 | 2000-08-08 | Bristol-Myers Squibb Company | Anti-regurgitation infant formula |
US5827544A (en) * | 1995-10-10 | 1998-10-27 | The Arab Pharmaceutical Manufacturing Co. Ltd. | Different way of management of neonatal hyperbilirubinemia |
ATE194264T1 (de) | 1995-12-15 | 2000-07-15 | Procter & Gamble | Getränke mit stabiler aroma-/trübungsemulsionen in anwesenheit von polyphosphate enthaltende konservierungssystemen und niedrigen gehalten an xanthangum |
US5681600A (en) | 1995-12-18 | 1997-10-28 | Abbott Laboratories | Stabilization of liquid nutritional products and method of making |
PT906029E (pt) | 1996-04-09 | 2002-11-29 | Du Pont | Produto de proteina de soja enriquecido em isoflavona e metodo para o seu fabrico |
US6365218B1 (en) * | 2000-02-04 | 2002-04-02 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
-
2000
- 2000-02-04 US US09/498,350 patent/US6365218B1/en not_active Expired - Lifetime
-
2001
- 2001-01-16 NZ NZ519695A patent/NZ519695A/en unknown
- 2001-01-16 KR KR1020027009974A patent/KR100767202B1/ko not_active IP Right Cessation
- 2001-01-16 WO PCT/US2001/001295 patent/WO2001056406A1/en active IP Right Grant
- 2001-01-16 CN CN01804563A patent/CN1400870A/zh active Pending
- 2001-01-16 ES ES01948924T patent/ES2261432T3/es not_active Expired - Lifetime
- 2001-01-16 HU HU0204382A patent/HUP0204382A3/hu unknown
- 2001-01-16 TR TR2002/01921T patent/TR200201921T2/xx unknown
- 2001-01-16 SK SK1256-2002A patent/SK12562002A3/sk unknown
- 2001-01-16 AU AU29490/01A patent/AU780438B2/en not_active Ceased
- 2001-01-16 PL PL01357134A patent/PL357134A1/xx unknown
- 2001-01-16 CA CA2396148A patent/CA2396148C/en not_active Expired - Lifetime
- 2001-01-16 DE DE60118387T patent/DE60118387T2/de not_active Expired - Lifetime
- 2001-01-16 EP EP01948924A patent/EP1251750B1/en not_active Revoked
- 2001-01-16 AT AT01948924T patent/ATE321462T1/de not_active IP Right Cessation
- 2001-01-16 CZ CZ20022743A patent/CZ20022743A3/cs unknown
- 2001-01-16 JP JP2001556112A patent/JP2003521501A/ja not_active Withdrawn
- 2001-01-16 MX MXPA02006938A patent/MXPA02006938A/es active IP Right Grant
- 2001-01-16 DK DK01948924T patent/DK1251750T3/da active
- 2001-01-16 PT PT01948924T patent/PT1251750E/pt unknown
- 2001-01-16 SI SI200120017A patent/SI21018A/sl not_active IP Right Cessation
- 2001-01-16 IL IL15032601A patent/IL150326A/xx not_active IP Right Cessation
- 2001-01-16 BR BR0106681-1A patent/BR0106681A/pt not_active IP Right Cessation
- 2001-02-02 TW TW090102265A patent/TWI241167B/zh not_active IP Right Cessation
- 2001-10-24 US US10/004,360 patent/US6589576B2/en not_active Expired - Lifetime
-
2002
- 2002-08-02 NO NO20023684A patent/NO20023684L/no not_active Application Discontinuation
- 2002-08-20 BG BG107019A patent/BG107019A/bg unknown
-
2003
- 2003-03-13 HK HK03101832.7A patent/HK1050983B/zh not_active IP Right Cessation
-
2006
- 2006-06-21 CY CY20061100828T patent/CY1108033T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI241167B (en) | Improved pediatric formula and methods for providing nutrition and improving tolerance | |
Abebe et al. | Nutritive value and sensory acceptability of corn-and kocho-based foods supplemented with legumes for infant feeding in Southern Ethiopia | |
US11246332B2 (en) | Non-dairy formulae | |
CN107752045A (zh) | 一种含蛋白质的组合物、食品及其制备方法和应用 | |
WO2007143046A1 (en) | Organic ready-to-feed liquid nutritional formula containing select carbohydrate combinations | |
Mudambi | Fundamentals of foods and nutrition | |
Dakia | Carob (Ceratonia siliqua L.) seeds, endosperm and germ composition, and application to health | |
CN114271335A (zh) | 乳制品及其制备方法 | |
Singh et al. | Food nutrition, science and technology | |
MXPA06013015A (es) | Nuevo proceso de elaboracion y estabilidad de un producto nutritivo de amaranto. | |
WO2012078032A1 (en) | Early stimulation of taste and/or flavour acceptance | |
Bogin | Milk and human development: an essay on the" milk hypothesis" | |
WO2004095944A2 (en) | High lactose infant nutrition formula | |
Yagmurovna | PHYSIOLOGICAL BASIS OF RATIONAL NUTRITION AND DAILY INTAKE OF NUTRIENTS | |
JP3358386B2 (ja) | 流動食品 | |
EP1049386A2 (en) | Process of improving the stability of vitamin d in a nutritional product containing hydrolyzed protein and product produced thereby | |
Bharodia et al. | Balanced Food for Better Health: Based on Food Security and Biotechnology | |
Sreemathy et al. | Nutrition and Biochemistry for Nurses, 3e | |
Breastfeeding | PEDIATRIC NUTRITION | |
Sharma | The problem of protein weaning foods in India | |
Rose | Dietary Facts and Fads | |
Amagloh et al. | A Report: Community-level acceptability and feasibility assessments of soy | |
Labuschagne et al. | Feeding babies: 6-12 months (part 1): infant nutrition | |
Amugune | Compositional, physical, micorocrobiological and keeping Quality of formulated dehulled toasted Maize-egg Flour weaning Food. | |
YEAR | NUTRITION AND DIETETICS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |